Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P186 | DOI: 10.1530/endoabs.35.P186

1UTIG-Endocrinology, Hospital U. Ramón y Cajal, Madrid, Spain; 2Department Biochemistry, Hospital U. Ramón y Cajal, Madrid, Spain; 3Department Endocrinology, Hospital de Melilla, Melilla, Spain; 4Department Endocrinology, Hospital U. Fuenlabrada, Fuenlabrada, Madrid, Spain.


Prevalence of hyperandrogenism (HA) and polycystic ovary syndrome (PCOS) in female to male transsexuals (FMT) is controversial. To known the prevalence of hyperandrogenism and PCOS in FMT, and their relation with insulin resistance (IR) and other cardiovascular risk factors (CVRF), we studied 77 Spanish consecutive FMT cases, the first ones who appeared in our Gender Unit between May 2007 and Dec 2008, aged 18–43 years. The subjects had never received hormonal treatment or sex reassignment surgery. Physical examination, ovary ultrasound, anthropometric measures, and metabolic and endocrine parameters were determined. Later the values obtained were compared according to the presence or absence of PCOS (Rotterdam 2003 criteria). Insulin resistance was determined using the homeostasis model assessment of insulin resistance (HOMA). The prevalence of HA was 49.4%, and those of PCOS was 36.4%, with IR in 27.6%, obesity in 19.5% and central obesity in 29.3%. In this population the prevalence of metabolic syndrome was 38.4% with ATP III criteria. Hyperandrogenemia was not only significantly related to obesity and other markers of IR but also with classic and emergent CVRF. In conclusion, FMT patients have a high prevalence of HA and PCOS, and with several CVRF. In FMT patients, the best marker of biochemical HA is the free androgen index.

Article tools

My recent searches

No recent searches.